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Recent studies have suggested the superiority of concomitant over sequential administration of chemotherapy and radiotherapy.
Docetaxel and cisplatin have demonstrated efficacy in advanced non-small-cell lung cancer (NSCLC). This study evaluated the safety,
toxicity, and antitumour activity of docetaxel/cisplatin with concurrent thoracic radiotherapy for patients with locally advanced
NSCLC. Patients with locally advanced NSCLC (stage IIIA or IIIB), good performance status, age p75 years, and adequate organ
function were eligible. Both docetaxel and cisplatin were given on days 1, 8, 29, and 36. Doses of docetaxel/cisplatin (mgm
 2) in the
phase I study portion were escalated as follows: 20/30, 25/30, 30/30, 30/35, 30/40, 35/40, 40/40, and 45/40. Beginning on day 1 of
chemotherapy, thoracic radiotherapy was given at a total dose of 60Gy with 2Gy per fraction over 6 weeks. In the phase I portion,
the maximum tolerated doses (MTD) among 33 patients were docetaxel 45mgm
 2 and cisplatin 40mgm
 2. The major dose-
limiting toxicity (DLT) was radiation oesophagitis. The recommended doses (RDs) for the phase II study were docetaxel 40mgm
 2
and cisplatin 40mgm
 2. A total of 42 patients were entered in the phase II portion. Common toxicities were leukopenia,
granulocytopenia, anaemia, and radiation oesophagitis, with frequencies of grade X3 toxicities of 71, 60, 24, and 19%, respectively.
Toxicity was significant, but manageable according to the dose and schedule modifications. Dose intensities of docetaxel and cisplatin
were 86 and 87%, respectively. Radiotherapy was completed without a delay in 67% of 42 patients. The overall response rate was
79% (95% confidence interval (CI), 66–91%). The median survival time was 23.4þ months with an overall survival rate of 76% at 1
year and 54% at 2 years. In conclusion, chemotherapy with cisplatin plus docetaxel given on days 1, 8, 29, and 36 and concurrent
thoracic radiotherapy is efficacious and tolerated in patients with locally advanced NSCLC and should be evaluated in a phase III
study.
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Stage III non-small-cell lung cancer (NSCLC) represents a large
patient population, accounting for approximately 30% of all
NSCLC patients (van Meerbeeck, 2001). This stage has been
intensively investigated for the last 10 years. Several studies and
meta-analyses have documented an improvement in patients with
stage III disease treated with chemotherapy followed by thoracic
radiation therapy, compared with radiation therapy alone (Marino
et al, 1995; Dillman et al, 1996; Sause et al, 2000). Full-dose
cisplatin-based chemotherapy with concurrent thoracic radiation
therapy produced encouraging results with relatively severe
toxicities (Lee et al, 1996; Reboul et al, 1996; Segawa et al, 2000).
Furthermore, results of a randomised trial demonstrated that
concurrent administration of cisplatin-based chemotherapy and
radiation significantly improved response rate and median
survival compared with sequential administration (Furuse et al,
1999); this finding is being confirmed by the Radiation Therapy
Oncology Group (RTOG) 9410 trial (Curran et al, 2000). Recently,
several new agents with potent activity in the treatment of NSCLC
have become available. The use of combination chemotherapy
including these new drugs has improved the survival of patients
with advanced NSCLC (Giaccone et al, 1998). The feasibilities
obtained with concomitant chemoradiotherapy regimens that
include new agents are being reported (Greco et al, 1996; Mauer
et al, 1998).
Cisplatin causes a synergistic effect when given simultaneously
with radiation both ex vivo and in vivo (Alvarez et al, 1978; Dewit,
1987). Docetaxel also shows a potential radiosensitising effect both
ex vivo and in vivo (Mason et al, 1997; Creane et al, 1999). The
combination of docetaxel and cisplatin shows additive effects in
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llung cancer cell lines (Aoe et al, 1999), and the antitumour
spectrums of cisplatin and docetaxel on various lung cancer cell
lines are completely different (Matsushita et al, 1999). In clinical
trials, the docetaxel/cisplatin combination is one of the most active
treatments of advanced NSCLC (Rodriguez et al, 2001). Moreover,
patients with relapsed NSCLC treated with single-agent docetaxel
had prolonged survival, even after receiving cisplatin-based
chemotherapy previously (Shepherd et al, 2000). Studies demon-
strated that a weekly administration schedule of docetaxel resulted
in markedly reduced myelosuppression compared with every 3-
week administration (Tomiak et al, 1994; Hainsworth et al, 1998).
Since the weekly schedule may improve therapeutic outcome by
increasing the dose intensity of docetaxel while reducing bone
marrow toxicity from concurrent radiation therapy, the divided
schedule of docetaxel on days on 1, 8, 29, and 36 was also
considered to have the same advantage.
Based on these concepts, this phase I/II study was conducted to
evaluate the safety, toxicity, antitumour activity, and survival
effects of chemotherapy consisting of docetaxel plus cisplatin given
on days 1, 8, 29, and 36 and concurrent thoracic radiation therapy
in patients with locally advanced NSCLC. We planned to
administer both cisplatin and docetaxel in as high doses and as
early as possible to pursue both local control and eradication of
distant micrometastasis.
PATIENTS AND METHODS
Eligibility criteria
Patients with histologically or cytologically confirmed NSCLC,
unresectable stage IIIA or IIIB disease, were eligible for the study;
however, those with T3N1 disease, malignant pleural effusion,
pericardial effusion, or pleural dissemination were excluded. Other
entry criteria included previously untreated disease, measurable
lesion, Eastern Cooperative Oncology Group (ECOG) performance
status (PS) (Oken et al, 1982) p1, age p75 years, and no history of
malignancy within 5 years of study. Before enrolment, each patient
had a complete medical history and physical, laboratory, and
staging assessments. The laboratory examinations consisted of
complete blood cell count (CBC), serum chemistry and tumour
marker analyses, 24-h creatinine clearance evaluation, arterial
blood gas analysis, urinalysis, electrocardiogram, and pulmonary
function tests. Staging work-up included chest plain radiographs,
computed tomography (CT) scan of the chest and abdomen
(ultrasonography of the abdomen could be substituted), magnetic
resonance imaging of the brain, radionuclide bone scan, and
bronchofiberscopy. Mediastinoscopy was not included in the
staging work-up. A mediastinal lymph node X10mm along the
short axis by CT scan was defined as a metastatic lymph node (N2-
3). Patients were required to have a white blood cell (WBC) count
X4000ml
 1, platelet (PLT) count X100,000ml
 1, haemoglobin
level X9gdl
 1, serum bilirubin levelp1.5mgdl
 1, serum aspar-
tate aminotransferase and alanine aminotransferase levels p2.5
times the upper normal limit, serum creatinine level p1.5mgdl
 1,
24-h creatinine clearance level X60mlmin
 1, and arterial oxygen
pressure (PaO2)X60mmHg. Patients were excluded if they had
markedly diminished vital capacity and/or forced expiratory
volume in 1s, any serious underlying diseases or complications,
or were women who were pregnant, breast feeding, or of child-
bearing age. Written informed consent was obtained from all
patients.
Response and toxicity evaluations
For the evaluation of response and toxicity, all patients underwent
a CBC and serum chemistry analysis two to three times a week,
urinalysis, and chest plain radiograph at least weekly during the
treatment and at least monthly thereafter; a CT scan of the chest
was taken on days 22 and 50 and every 3 months for 2 years;
examinations performed at staging work-up were repeated after
the completion of treatment. Response was assessed by extramural
reviewers using ECOG criteria (Oken et al, 1982). The response
rate was determined on an ‘intention-to-treat’ basis. Toxicity was
assessed and graded using ECOG common toxicity criteria (Oken
et al, 1982). The grading of acute oesophageal and pulmonary
toxicities due to radiation was in accordance with RTOG/European
Organization for Research and Treatment of Cancer (EORTC)
radiation acute toxicity criteria (Cox et al, 1995). Dose limiting
toxicity (DLT) was defined as grade X3 haematologic toxicity
lasting 3 days or longer, grade X3 radiation oesophagitis, or any
nonhaematologic grade 3 or higher toxicities except hair loss and
nausea/vomiting.
Phase I study
The primary end point of the phase I portion of the study was to
determine the maximum-tolerated doses (MTDs) and the recom-
mended doses (RDs) of docetaxel and cisplatin for the phase II
study when combined with 60Gy of concurrent thoracic radiation
therapy for patients with locally advanced and surgically
unresectable NSCLC.
Dose escalation scheme Dose levels of docetaxel and cisplatin are
shown in Table 1. At least three patients were entered at each dose
level. If a DLT occurred in two of three initial patients at a
particular dose level, then three additional patients were treated at
the same dose level to define the frequency of that toxicity. If three
of three patients or at least four of six patients experienced the
DLT, enrolment at this dose level was ceased, the dose level was
determined as the MTD, and the preceding dose level was
designated as the RD for the phase II study.
Treatment schedule and modifications The treatment scheme is
shown in Figure 1. Docetaxel was administered intravenously over
1h followed by 1-h infusion of cisplatin before radiation therapy.
Before and after cisplatin instillation, all patients received 2000–
2500ml of normal saline and 5% glucose by infusion over 4h.
Prophylactic antiemetic therapy using 5-hydroxytriptamine type
III receptor blocker and dexamethasone was given to all patients.
Patients experiencing grade 3 granulocytopenia with infection or
grade 4 leukopenia or granulocytopenia subsequently received
Table 1 Dose-escalation scheme and principal toxicities in the phase I
portion of the trial (n¼33)
Dose level 1 2 3 4 5 6 7 8
Docetaxel (mgm
 2) 2 0 2 53 03 03 0 3 54 0 4 5
Cisplatin (mgm
 2) 3 0 3 03 03 54 0 4 04 0 4 0
No. of patients 6 3333 36 6
N o . o f D L T s 2 0001 01 4
Principal toxicity
a
Oesophagitis G3 2 (2)
b 1 (1) 2 (2)
Liver G3 1 (1)
Granulocytopenia G3 1 1(1) 1 4 (1) 2 (1)
G4 2 (1)
Anaemia G3 1 1
G4 1 1
Thrombocytopenia G3 1 (1)
DLT¼dose-limiting toxicity; G3¼grade 3; G4¼grade 4.
aToxicity was assessed and
graded using ECOG common toxicity criteria (Oken et al, 1982), and grading of acute
oesophageal toxicity due to radiation was evaluated in accordance with RTOG/
EORTC radiation acute toxicity criteria (Cox et al, 1995).
bNumber of patients with
grade 3 or 4 toxicity (numbers in parentheses indicate number of patients with the
DLT).
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lrecombinant human granulocyte colony-stimulating factor (rhG-
CSF: 2mgkg
 1) subcutaneously until leucocyte or neutrophil count
recovered to X5000ml
 1 or X2000ml
 1, respectively. Chemother-
apy dose and schedule modifications for toxicity are shown in
Table 2.
Radiation therapy was administered from day 1 of chemother-
apy using a linear accelerator (6–10MeV), in 2Gy single daily
fractions for five consecutive days each week to a total dose of
60Gy.
Treatment planning was constructed for a curative radiation
field using chest plain radiograph and contrast-enhanced CT scan
before concomitant chemoradiotherapy. Principally, the initial
radiation field was planned not to exceed 50% of one lung. The
initial dose (B40Gy) was administered to the original volume that
consisted of primary tumour including the movement area by
respiration and the ipsilateral hilum with 2cm margin, and all
enlarged mediastinal lymph nodes (X10mm along the short axis)
detected by CT scan with 1cm margin, extending inferiorly to 3cm
below the carina if subcarinal lymph nodes were involved. Other
prophylactic radiation fields were not set up. The supraclavicular
region was not routinely included if lymph nodes metastasis or
primary tumour invasion was not detected. Subsequently, an
additional 20Gy dose was administered to the boost volume,
including the sites of primary tumour and hilar/mediatinal lymph
nodes according to the tumour and lymph nodes shrinkage
determined by contrast-enhanced CT scan on day 29 or later. The
original volume was treated with an anterior–posterior parallel-
opposed pair of portals, and the boost volume was treated with the
same pair or with a pair of oblique fields if the cumulative
radiation dose to the spinal cord exceeded 40Gy. Radiation
therapy dose and schedule modifications for toxicity are shown in
Table 2.
The patients were carefully treated on an inpatient basis during
the concomitant chemoradiotherapy.
Phase II study
The primary end points of the phase II portion of the study
were objective response rate and safety of this combined treatment
modality at the RD level. The secondary end point was the
2-year survival rate. The same patient eligibility requirements,
treatment schedules, dose and schedule modifications, and
response and toxicity criteria as in the phase I portion of the
study applied.
Statistical considerations
The sample size for the phase II study portion was calculated as
36 patients on the assumption that 70% of patients would respond,
with a 95% confidence interval (CI) 7 15%. Assuming that 10% of
patients would not be evaluable for response, the accrual goal was
42 patients, including those who received chemoradiotherapy at
the RD level in the phase I portion of the trial. The survival time
was defined as the period from initiation of treatment to death or
last follow-up evaluation, and event-free survival was defined as
the period from initiation of treatment to PD or death due to
causes other than NSCLC. The survival and event-free survival
curves were calculated using the Kaplan and Meier method.
RESULTS
Patient characteristics
Between June 1997 and December 1999, 69 patients at Okayama
University Hospital and 11 affiliated hospitals in Japan were
enrolled in this phase I/II study. All patients had ECOG PS of 0–1.
In the phase I portion of the study, 33 patients were treated at one
of eight dose levels (Table 1). The patients comprised 30 men and
three women with a median age of 63 years (range, 29–75 years).
Fourteen (42%) patients had squamous cell carcinoma, 13 (39%)
adenocarcinoma, three (9%) large-cell carcinoma, and three (9%)
unclassified carcinoma. Nine (27%) patients had stage IIIA and 24
(73%) stage IIIB disease. Forty-two patients, including six who had
received chemoradiotherapy at the RD level in phase I, were
analysed in the phase II portion of the study (Table 3). Overall, 36
men and six women with a median age of 67 years (range, 29–75
years) were included. Twenty-six (62%) patients had squamous
cell carcinoma, 12 (29%) adenocarcinoma, and four (10%)
unclassified carcinoma. Eight (19%) patients had stage IIIA and
2Gy per fraction; once daily; total dose, 60Gy
Chemotherapy
Chest radiation
therapy
Docetaxel
Cisplatin
Day
1 8 29 36 42
Figure 1 Treatment scheme of the phase I/II study of concurrent
chemoradiotherapy with cisplatin and docetaxel in patients with advanced
NSCLC. The arrow indicates shrinkage of the radiation field at a total dose
of 40Gy.
Table 2 Chemotherapy and radiotherapy dose and schedule modifications for toxicity
a
Toxicity Modification
Chemotherapy
Grade X3 leukopenia, granulocytopenia, thrombocytopenia, on days 8 or 36 Docetaxel and cisplatin withheld
Grade X3 leukopenia, granulocytopenia, thrombocytopenia, on day 29 Chemotherapy postponed until toxicity recovered to grade 2
Grade 2 leukopenia, granulocytopenia, thrombocytopenia on day 8, 29, or 36 Doses of both drugs reduced by 5mgm
 2
24-h creatinine clearance 30–60mlmin
 1, or serum creatinine 1.5–2.0mgdl
 1 Cisplatin dose reduced to 30mg m
 2
Creatinine clearance o30mlmin
 1, or serum creatinine 42.0mgdl
 1 Cisplatin withheld
Systemic oedema or fluid retention on day of chemotherapy administration Docetaxel withheld
Nonhaematologic grade X3 toxicity, except for hair loss or nausea/vomiting Chemotherapy postponed until recovery
Radiotherapy
Grade X3 radiation oesophagitis Radiation withheld until recovery to grade p2
Lung toxicity (10TorrkPaO2 from baseline) Radiation withheld until PaO2 decrease is o10Torr
Grade 3 granulocytopenia with infection or grade
4 leukopenia or granulocytopenia
Radiation discontinued and rhG-CSF (2mgkg
 1)
administered until leucocyte count X5000ml
 1 or neutrophil count X2000ml
 1
Grade X3 thrombocytopenia Radiation withheld until platelet count X25000ml
 1
aChemotherapy and radiotherapy were discontinued if toxicities did not resolve within 12 weeks.
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l34 (81%) had stage IIIB disease including three (7%) with swelling
of supraclavicular lymph nodes. Five (12%) patients had 5% or
more weight loss within 6 months.
Phase I study
Dose escalation and toxicity The dose-escalation scheme and
principal toxicities observed in the phase I portion of the study are
summarised in Table 1. At the first dose level, two of the initial
three patients developed grade 3 radiation oesophagitis that lasted
for 19 and 8 days, respectively, and one of the two patients had
grade 3 hepatic toxicity. None of three additional patients treated
at the first dose level developed DLT. At dose level 5, one patient
encountered grade 3 granulocytopenia on day 72, which continued
to day 82. Although six patients were enrolled at dose level 7 for
the safety, only one patient experienced DLT (grade 3 radiation
oesophagitis and grade 3 granulocytopenia). Four of six patients at
dose level 8 developed DLT (two with grade 3 radiation
oesophagitis, one each with grade 4 granulocytopenia, and grade
3 granulocytopenia and thrombocytopenia). The MTD was
determined to be dose level 8 (docetaxel 45mgm
 2, cisplatin
40mgm
 2), and dose level 7 (docetaxel 40mgm
 2, cisplatin
40mgm
 2) was adopted as the RD for the phase II study.
Response and survival Among 33 entered patients, one (3%) had
complete response (CR), 22 (67%) had partial response (PR), eight
(24%) had no change (NC), and one (3%) had progressive disease
(PD), for an overall response rate of 70% (95% CI, 55–85%).
Overall and event-free survival curves for the 33 patients are
shown in Figure 2A. At a median follow-up time of 39 months
(range, 32–51 months), 21 (64%) patients had died and 12 (36%)
were still alive without disease. The causes of death were directly
related to NSCLC in 20 patients and unrelated in one (suicide).
Overall survival rates at 1, 2, and 3 years were 76, 49, and 36%,
respectively. The median survival time was 24 months. Event-free
survival rates (mean) at 1, 2, and 3 years were 39, 36, and 36%,
respectively.
Phase II study
Response and survival Responses in 42 patients entered in the
phase II portion of the study were CR in one (2%), PR in 32 (76%),
NC in eight (19%), and PD in one (2%), for an overall response
rate of 79% (95% CI, 66–91%). Figure 2B shows overall survival
for the 42 patients. At a median follow-up time of 26 months
(range, 21–36 months), 20 (48%) patients had died and 22 (52%)
were still alive. The causes of death were directly related to NSCLC
in 19 patients and pneumonia and radiation pneumonitis in one.
Overall survival rates (mean) at 1 and 2 years were 76 and 54%,
respectively. The median survival time was 23.4þ months. Event-
free survival rates at 1 and 2 years were 55 and 38%, respectively.
Toxicity Toxicities observed in 42 patients during treatment and
follow-up are listed in Tables 4 and 5. The most common toxicity
was leukopenia, which often occurred in conjunction with
granulocytopenia. Grade X3 leukopenia and granulocytopenia
occurred in 30 (71%) and 25 (60%) patients, respectively.
Recombinant human granulocyte colony stimulating factor was
administered to 18 (43%) patients for a median duration of 4 days
(range, 1–10 days). Grade X3 thrombocytopenia and anaemia
occurred in 10 (24%) and three (7%) patients, respectively. Grade
X3 radiation oesophagitis, radiation pneumonitis, hepatic dys-
function, and diarrhoea occurred in eight (19%), two (5%), one
(2%), and three (7%) patients, respectively. The median WBC
count nadir in eight patients with grade X3 radiation oesophagitis
was 1150ml
 1 (range, 500–2300ml
 1); grade X3 leukopenia also
occurred in 88% of these eight patients. Overall, 32 (76%) patients
experienced any grade X3 toxicity (haematologic only, 45%;
nonhaematologic only, 5%; both, 26%). At day 102 from the
beginning of radiation therapy, one patient died of pneumonia and
radiation pneumonitis. This patient was admitted to a local
hospital because of acute respiratory failure, was treated as
pneumonia, but died within a week. Autopsy was not carried out.
Initial relapse site Nineteen patients were evaluable for sites of
initial relapse in the phase II portion. The primary site was the first
Table 3 Patient characteristics (phase II portion)
No. of patients
No. of patients evaluated/eligible 42/42
Median age, year (range) 67 (29–75)
Sex: male/female 36/6
ECOG PS: 0/1 18/24
Weight loss
5% or more 5
Less than 5% 37
Histology
Adenocarcinoma 12
Squamous cell carcinoma 26
Unclassified 4
Stage of disease: IIIA/ IIIB 8/34
TNM classification
T2N2M0 5
T3N2M0 3
T1N3M0 2
T2N3M0 5
T3N3M0 4
T4N0M0 3
T4N1M0 3
T4N2M0 15
T4N3M0 2
ECOG¼Eastern Corporative Oncology Group; PS¼performance status.
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Figure 2 (A) Overall (solid line) and event-free (dotted line) survival for
33 patients with locally advanced NSCLC in the phase I portion of the
study. (B) Overall (solid line) and event-free (dotted line) survival for 42
patients with locally advanced NSCLC in the phase II portion of the study.
Censored cases are denoted by tics.
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lsite of failure in nine patients (nine without and one with distant
metastasis). Distant metastasis was the first site of the failure in 10
patients. Failure sites were as follows: lung (n¼3), adrenal gland
(n¼2), bone (n¼2), penis (n¼1), brain (n¼1), and skin (n¼1).
Completion of therapy As shown in Table 6, 36 of 42 (86%)
patients completed chemotherapy as planned. One patient skipped
chemotherapy only on day 8. Doses of cisplatin and docetaxel were
reduced in two (5%) and seven (17%) patients, respectively.
Reasons for not completing chemotherapy were toxicity (n¼3),
patient refusal (n¼1), or physician discretion (n¼2). The median
interval (range) between chemotherapy courses 1 and 2, courses 2
and 3, and courses 3 and 4 were 7 days (7–12 days), 21 days (21–
51 days), and 7 days (7–33 days), respectively. Ratios of actual to
projected doses of cisplatin and docetaxel were 96 and 95%,
respectively. As shown in Table 7, 28 (67%) and 24 (57%) patients
were able to receive chemotherapy on time on days 29 and 36,
respectively. On day 43 or later, 13 (31%) patients received cycles 3
and/or 4 of chemotherapy with or without concurrent radio-
therapy. Accordingly, the actual dose intensities of cisplatin and
docetaxel were 87 and 86%, respectively.
A total of 36 (86%) patients completed radiation therapy
(Table 8); however, eight (19%) required a rest from radiation
(median, 10 days; range, 4–28 days) due to granulocytopenia
(n¼6), radiation oesophagitis (n¼1), and granulocytopenia plus
oesophagitis (n¼1). Reasons for not completing radiation therapy
were radiation oesophagitis (n¼3), radiation pneumonitis (n¼1),
patient refusal (n¼1), or physician discretion (n¼1). The total
mean radiation doses and durations were 57.2Gy and 45.6 days,
respectively. Overall, 57% of 42 patients completed both che-
motherapy and radiation therapy without any modifications
according to the protocol.
Three (7%) patients who achieved PR (determined by CT scan)
after completing chemoradiotherapy underwent surgery, although
this was not part of the study protocol. Postsurgically, two patients
with T4N2 disease were downstaged to a pathological CR and
pT1N0 disease, and one patient with T2N2 disease still had pT1N2
disease. Microscopic assessment of pT1N0 and pT1N2 tumour
samples demonstrated only a few scattered viable tumour cells in
necrotic tissue of a primary tumour and/or a mediastinal lymph
node. These three patients were still alive without recurrence at the
last follow-up evaluation (25, 27, and 36 months, respectively).
DISCUSSION
This phase I/II study demonstrated encouraging results with
concomitant chemoradiotherapy using cisplatin and docetaxel in
patients with advanced NSCLC. In the phase I portion of the study,
the maximum tolerated chemotherapy doses were determined to be
docetaxel 45mgm
 2 and cisplatin 40mgm
 2. The most common
DLTs were radiation oesophagitis and myelosuppression. Recom-
mended doses for the phase II study were docetaxel 40mgm
 2 and
cisplatin 40mgm
 2. In the phase II portion of the study, 79% of
patients responded to concomitant chemoradiotherapy with
cisplatin and docetaxel, with a median survival time 423 months,
and survival rates of 76% at 1 year and 54% at 2 years.
One reason for the favourable results may be the dose intensities
of cisplatin and docetaxel achieved in this trial. The doses of
docetaxel and cisplatin with concurrent standard radiotherapy
(60Gy in 6 weeks) were escalated more than we expected in the
phase I portion. We did not plan dose levels 6–8 at the beginning
of this trial, because standard doses without concurrent thoracic
radiation therapy in Japan were docetaxel 60mgm
 2 and cisplatin
80mgm
 2 at a 3-week interval (Kubota et al, 2002), which
corresponded to docetaxel 30mgm
 2 and cisplatin 40mgm
 2 on
days 1 and 8 at dose level 5. In the phase II portion, the projected
dose intensity of both cisplatin and docetaxel in combination with
60Gy standard thoracic radiation therapy was 27mgm
 2 week
 1,
which was comparable to full doses of docetaxel and cisplatin at a
3-week interval (Zalcberg et al, 1998). This study demonstrated
that the divided schedule could result in similar dose intensities as
a weekly schedule. Thus, chemotherapy doses with concomitant
chemoradiotherapy in the current trial were similar to or higher
than those in the previous phase II trials that did not include
concurrent thoracic radiotherapy.
Another advantage of the present regimen is the flexibility of the
treatment schedule. To reduce toxicity, we often use the divided
schedule on days 1 and 8 as previously reported (Ueoka et al, 1998,
1999, 2001; Date et al, 2002). We conducted a previous,
unsuccessful dose-escalation trial of cisplatin/etoposide che-
motherapy in a divided schedule with concurrent thoracic
radiation therapy (Segawa et al, 2003). In that trial, we strictly
fixed the chemotherapy administration on days 29 and 36, and
dose and schedule modifications were inhibited on days 29 and 36.
Based on that failure, this protocol included the flexible dose and
schedule modifications. Accordingly, chemotherapy could be fully
administered on days 1 and 8 to all except one patient. On days 29,
36, or later, dosing was individualised according to the prescribed
dose and schedule modifications.
Toxicity, although significant, was tolerable according to the
dose and schedule modifications of the protocol. In the phase II
portion of the study, 76% of 42 patients experienced any grade X3
toxicity, most commonly grade X3 granulocytopenia. However,
57% of 42 patients completed both chemotherapy and radiation
therapy without any modifications, and 88% of 42 patients were
able to complete the planned chemotherapy and 86% completed
radiation therapy according to dose and schedule modifications of
the protocol. The dose modifications of chemotherapy based on
haematogic toxicity were carried out on days 8, 29, and 36.
Leukopenia/granulocytopenia is transient and easily controlled by
rhG-CSF, and life-threatening infections or treatment-related
Table 4 Haematologic toxicities (phase II portion) (n¼42)
No. of patients with grade
0 1 2 3 4 % of toxicities
grade X3
Leukopenia 0 2 10 24 6 71
Granulocytopenia 2 3 12 18 7 60
Anaemia 1 12 19 9 1 24
Thrombocytopenia 35 2 2 3 0 7
Haematologic toxicity was assessed and graded using ECOG common toxicity
criteria (Oken et al, 1982).
Table 5 Nonhaematologic toxicities (phase II portion) (n¼42)
No. of patients with grade
012345 % o f toxicities
grade X3
Nausea/vomiting 9 13 15 5 0 0 11.9
Diarrhoea 28 6 5 2 1 0 7.1
Stomatitis 37 4 0 0 1 0 2.4
Neurologic 40 2 0 0 0 0 0
Liver 38 1 2 1 0 0 2.4
Renal dysfunction 41 1 0 0 0 0 0
Fever 36 1 5 0 0 0 0
Alopecia 2 28 12 — — — —
Oesophagitis 13 12 9 7 1 0 19.0
Pneumonitis 38 3 0 1 0 1 4.8
Nonhaematologic toxicity was assessed and graded using ECOG common toxicity
criteria (Oken et al, 1982), and grading of acute oesophageal and pulmonary toxicities
due to radiation was in accordance with RTOG/EORTC radiation acute toxicity
criteria (Cox et al, 1995).
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oesophagitis occurred in 19% of patients, which was comparable to
that occurring with other concomitant chemoradiotherapy regi-
mens (e.g., 20% with cisplatin and etoposide (Albain et al, 2002),
26% with cisplatin and paclitaxel (Robert et al, 2002), and 46%
with carboplatin and paclitaxel (Choy et al, 1998)). We have
observed a low incidence of grade X3 radiation pneumonitis
among patients analysed at a median follow-up time of 26 months
in the phase II portion. When paclitaxel/cisplatin was combined
with concurrent radiation therapy, 20% of grade X3 late lung
toxicity including 8% of grade 5 was reported (Robert et al,
2002). Mauer also reported two cases (7%) of grade 5 pulmonary
toxicity using docetaxel with concurrent radiotherapy. In our
trial, the incidence of grade X3 radiation pneumonitis is low.
Although careful follow-up for late radiation pneumonitis is
needed, there was no additional grade X3 radiation pneumonitis
in April 2003.
Chemotherapy was postponed or skipped on day 29 in 33% of
the patients and on day 36 in 43% of patients, although the real/
projected doses of cisplatin and docetaxel were 96 and 95%,
respectively. Radiation treatment delays were observed in 19% of
patients, and 14% did not complete radiation therapy. While
treatment compliance is very important, a goal of chemora-
diotherapy for locally advanced NSCLS is cure. We increased the
chemotherapy doses to the limit, even if that slightly decreased
compliance to radiotherapy. In this study, dose and schedule
modifications worked very well, and there was no acute treatment-
related death.
According to the current phase II trials, concomitant chemor-
adiotherapy is required to attain median survival time exceeding
17 months, survival rates X65% at 1 year and X35 % at 2 years,
and p50% grade 3/4 toxicity in stage III NSCLC (Gandara et al,
2001). Survival has to be balanced against toxicity and compliance.
The current trial succeeds in achieving satisfactory 1-year and 2-
year survival rates, whereas improvements are needed in reducing
toxicities and enhancing compliance in the future.
Recently, the Southwest Oncology Group (SWOG) trial 9504
evaluated docetaxel as consolidation therapy after full-dose cisplatin
and etoposide with concurrent radiotherapy (Gandara et al, 2001).
The updated results were very impressive, with a 26-month median
survival time and survival rates of 76% at 1 year and 53% at 2 years,
although patients with pathological stage IIIB disease were enrolled.
Direct comparison of the results is very difficult, because our study
included eight (19%) patients with stage IIIA disease in the phase II
portion and excluded minimal pathological N2 or N3 disease by
mediastinoscopy. The treatment period of our schedule was shorter
by at least 9 weeks compared with that in SWOG 9504. For the
patients with stage III disease who receive adjuvant surgery, the
shorter treatment period might have an advantage.
Many clinical trials are now assessing combinations of taxanes,
platinums, and concurrent radiotherapy for patients with locally
advanced NSCLC. Frasci et al (1997) suggested that weekly
cisplatin/paclitaxel could be safely administered with concurrent
standard radiotherapy. Robert et al (2002) reported the feasibility
of cisplatin/paclitaxel and conventional radiation therapy. Wu et al
(2002) reported that the RDs of docetaxel and cisplatin adminis-
tered weekly with concurrent radiotherapy were both 20mgm
 2.
Choy et al (1998) reported a phase II study of weekly paclitaxel
(50mgm
 2) and carboplatin at area under the curve 2 with
concurrent radiation therapy.
It is very difficult to select the ideal drugs for concurrent
radiotherapy. We prefer to use cisplatin in a concomitant
chemoradiotherapy regimen when we pursue the CR. First,
Schaake-Koning et al (1992) demonstrated that daily cisplatin
acted as a radiosensitiser in a phase III trial as well as in ex vivo
and in vivo experiments. Second, although a Hoosier Oncology
Table 6 Chemotherapy dose intensity
Chemotherapy (cycle no.)
No. 1 No. 2 No. 3 No. 4 All Dose intensity
a
Cisplatin 87719%
Real/projected dose (%) 101 99 95 89 96
No. of patients administered 42 41 40 37 36
b
No. of patients administered with dose reduction 0 0 2 0 2
Docetaxel 86720%
Real/projected dose (%) 101 99 93 87 95
No. of patients administered 42 41 40 37 36
b
No. of patients administered with dose reduction 0 0 7 6 7
Median interval between Chemotherapy, days (range) 7 21 7
(7–12) (21–51) (7–33)
aIndicates administered dose per time unit/projected dose per time unit (mean7s.d.).
bOne patient skipped chemotherapy only on day 8.
Table 7 Schedule of chemotherapy compliance
Days from the beginning of
concomitant chemoradiotherapy
Cycle No. 1
(on day 1)
No. 2
(on day 8)
No. 3
(on day 29)
No. 4
(on day 36)
No. 3 and/or
No. 4 (on day
43 or later)
No. of patients administered (%) 42 (100) 41 (98) 28 (67) 24 (57) 13 (31)
Table 8 Compliance with radiotherapy
Thoracic radiation therapy No. (%) of patients
Completed 36 (86)
without rest period 28 (67)
with rest period 8 (19)
Not completed 6 (14)
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lGroup study reported that cisplatin administered every 3 weeks
and concurrent radiotherapy did not improve overall survival, the
data indicated possible improved long-term survival with con-
comitant chemoradiotherapy (Blanke et al, 1995). Patients treated
with the combination therapy had 3- and 5-year survival rates of 9
and 5%, respectively, whereas the rates were 3 and 2% with
radiation alone. Recent results from a large, international phase III
trial comparing docetaxel/cisplatin, docetaxel/carboplatin, and
vinorelbine/cisplatin seem to favour the docetaxel/cisplatin
combination even in patients with advanced NSCLC (Rodriguez
et al, 2001). Moreover, paclitaxel/cisplatin has shown significantly
longer median survival when compared to paclitaxel/carboplatin
(Rosell et al, 2002).
Taxanes are also very attractive drugs for concomitant
chemoradiotherapy. Taxanes are known to enhance radiation
sensitivity of tumour cells through processes including the
following: (1) reoxygenation of hypoxic cells within the tumour,
since taxane-killed cells are removed by apoptosis (Milas et al,
1995), (2) arrest of cells in both G2 and M phases, the most
radiation-sensitive phases of the cell cycle (Tishler et al, 1992), and
(3) mobilisation of T cells and natural killer cells to the tumour
(Mason et al, 2001). Although the majority of studies including
taxanes have assessed paclitaxel, radiosensitisation with docetaxel
has also been demonstrated both ex vivo and in vivo. (Mason et al,
1997; Creane et al, 1999) Moreover, docetaxel combined with
radiation showed a synergistic or additive effect in NSCLC cell
lines tested both ex vivo and in vivo (Nishizaki et al, 2001). In a
clinical trial of docetaxel used weekly at the MTD, no grade 4
myelosuppression or peripheral neuropathy was observed (Hains-
worth et al, 1998). The divided schedule might also prove
advantageous when combined with cisplatin and concurrent
radiotherapy based on nonoverlapping toxicities like a weekly
schedule of docetaxel.
There is no evidence of the superiority of concomitant
chemoradiotherapy using new drugs (taxanes, vinorelbine)/cispla-
tin as compared with the older standard, full-dose, cisplatin-based
chemotherapy. Our group is now conducting a phase III trial of
docetaxel/cisplatin vs mitomycin/vindesine/cisplatin with concur-
rent thoracic radiotherapy.
In conclusion, a regimen comprising cisplatin, docetaxel, and
radiation is an exciting approach in the treatment of locally
advanced NSCLC. The results of our study showed that
chemotherapy consisting of cisplatin and docetaxel given on days
1, 8, 29, and 36 with concurrent radiation therapy might be the
effective treatment modality in patients with locally advanced
NSCLC.
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